Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.57 |
| ▸ | LMNA | P02545 | 4/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | PLAU | P00749 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 3/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | GFER | P55789 | 1/20 | 0.55 |
| ▸ | PGR | P06401 | 4/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18546034 | 0.81 | CYP19A1 (0.73) | SMN1; SMN2ALDH1A1LMNAHPGDMEN1 | |
| SCHEMBL18530465 | 0.78 | SMN1; SMN2 (0.79) | SMN1; SMN2ALDH1A1LMNAGAAMAPK1 | |
| SCHEMBL14433971 | 0.77 | LMNA (0.51) | SMN1; SMN2LMNAMAPTPKMTP53 | |
| SCHEMBL29011587 | 0.77 | LMNA (0.62) | SMN1; SMN2ALDH1A1LMNAHPGDGAA | |
| SCHEMBL5187428 | 0.77 | PGR (0.64) | SMN1; SMN2ALDH1A1LMNAHPGDGAA | |
| SCHEMBL6928661 | 0.77 | UCHL1 (0.71) | SMN1; SMN2ALDH1A1LMNAGAAMAPK1 | |
| SCHEMBL8752431 | 0.77 | UCHL1 (0.71) | SMN1; SMN2ALDH1A1LMNAGAAMAPK1 | |
| SCHEMBL790294 | 0.77 | GAA (0.86) | SMN1; SMN2ALDH1A1LMNAPLAUGAA | |
| SCHEMBL1607332 | 0.76 | HSD17B10 (0.44) | ALDH1A1LMNAGAAMAPT | |
| SCHEMBL3643588 | 0.76 | CA2 (0.48) | GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030191309-A1 | N-substituted arylsulfonylamino hydroxamic acids useful as inhibitors of C-proteinase and for treating or preventing disorders related to unregulated collagen production | HO WEN-BIN (US) | 2003-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191309-A1 | N-substituted arylsulfonylamino hydroxamic acids useful as inhibitors of C-proteinase and for treating or preventing disorders related to unregulated collagen production | MMP1, MMP13, COL14A1 | SMN1; SMN2 3122/4885ALDH1A1 1188/4885LMNA 779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.